Muvalaplin
Lilly Advances Muvalaplin into Phase III in China: First Oral Lp(a)-Lowering Therapy Targeting MACE Risk
Lilly initiates Phase III trial of Muvalaplin in China and globally to reduce MACE in adults with elevated Lp(a), marking the first oral therapy in this class.